Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 28;11(3):675-681.
doi: 10.14218/JCTH.2022.00217. Epub 2023 Jan 4.

Role of Hydrogen Sulfide and Hypoxia in Hepatic Angiogenesis of Portal Hypertension

Affiliations
Review

Role of Hydrogen Sulfide and Hypoxia in Hepatic Angiogenesis of Portal Hypertension

Huaxiang Yang et al. J Clin Transl Hepatol. .

Abstract

The pathogenesis of portal hypertension remains unclear, and is believed to involve dysfunction of liver sinusoidal endothelial cells (LSEC), activation of hepatic stellate cells (HSC), dysregulation of endogenous hydrogen sulfide (H2S) synthesis, and hypoxia-induced angiogenic responses. H2S, a novel gas transmitter, plays an important role in various pathophysiological processes, especially in hepatic angiogenesis. Inhibition of endogenous H2S synthase by pharmaceutical agents or gene silencing may enhance the angiogenic response of endothelial cells. Hypoxia-inducible factor-1 (HIF-1) is the main transcription factor of hypoxia, which induces hepatic angiogenesis through up-regulation of vascular endothelial growth factor (VEGF) in HSC and LSEC. H2S has also been shown to be involved in the regulation of VEGF-mediated angiogenesis. Therefore, H2S and HIF-1 may be potential therapeutic targets for portal hypertension. The effects of H2S donors or prodrugs on the hemodynamics of portal hypertension and the mechanism of H2S-induced angiogenesis are promising areas for future research.

Keywords: Angiogenesis; Hydrogen sulfide; Hypoxia; Hypoxia-inducible factor; Portal hypertension.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interests related to this publication.

Figures

Fig. 1
Fig. 1. Pathways of HIF-1α synthesis/degradation under normoxic and hypoxic conditions.
Translation of HIF-1α protein under normoxic conditions is mainly dependent on the activation of PI3K/Akt/mTOR signaling pathway. HIF-1α is hydroxylated by PHD under normoxic conditions and subsequently binds to VHL protein to form a complex. The complex in turn recruits ubiquitin ligases to target HIF-1α for proteasomal degradation. Under hypoxic conditions, H2S induces phosphorylation of eIF2α, thereby inhibiting HIF-1α translation. In addition, H2S reverses hypoxia-induced inhibition of PHD activity and thus promotes the degradation of HIF-1α. HIF-1α, hypoxia-inducible factor 1α; PHD, prolyl hydroxylase; VHL, von Hippel-Lindau; H2S, hydrogen sulfide; eIF2α, eukaryotic translation initiation factor 2α.
Fig. 2
Fig. 2. Proposed interactions among H2S, VEGF, and HIF-1.
The binding of VEGF to VEGFR2 may activate CSE through a calcium-dependent pathway, which in turn promotes endogenous H2S production. Nucleophilic attack by H2S on the disulfide bond between Cys 1045-1024 leads to reduction of the disulfide bond and enhances VEGFR2 tyrosine kinase activity. CBS-derived and CSE-derived H2S enhances the stability and transcriptional activity of Sp1, which further promotes the transcription of VEGFR2. H2S results in increased HIF-1α levels, DNA binding, and transcriptional activity. VEGFR2, vascular endothelial growth factor receptor 2; VEGF, vascular endothelial growth factor; CSE, cystathionine-γ lyase; CBS, cystathionine-β synthase; HIF, hypoxia-inducible factor; HRE, hypoxia response element; Sp1, specificity protein 1; H2S, hydrogen sulfide.

Similar articles

Cited by

References

    1. Veldhuijzen van Zanten D, Buganza E, Abraldes JG. The Role of Hepatic Venous Pressure Gradient in the Management of Cirrhosis. Clin Liver Dis. 2021;25(2):327–343. doi: 10.1016/j.cld.2021.01.002. - DOI - PubMed
    1. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VII Faculty Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–974. doi: 10.1016/j.jhep.2021.12.022. - DOI - PMC - PubMed
    1. Gracia-Sancho J, Marrone G, Fernández-Iglesias A. Hepatic microcirculation and mechanisms of portal hypertension. Nat Rev Gastroenterol Hepatol. 2019;16(4):221–234. doi: 10.1038/s41575-018-0097-3. - DOI - PubMed
    1. Mauro E, Gadano A. What’s new in portal hypertension? Liver Int. 2020;40(Suppl 1):122–127. doi: 10.1111/liv.14366. - DOI - PubMed
    1. Waseem N, Chen PH. Hypoxic Hepatitis: A Review and Clinical Update. J Clin Transl Hepatol. 2016;4(3):263–268. doi: 10.14218/JCTH.2016.00022. - DOI - PMC - PubMed